TrialPath
Recruiting

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

NCT05356039 · Umeå University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study
About this study
This is a multicenter pragmatic prospective observational study including Nordic hospitals treating patients with borderline resectable and locally advanced pancreatic cancer. Eligibility will be assessed at regional multidisciplinary tumor boards. Patients with borderline resectable and locally advanced (non-endocrine) pancreatic cancer according to the National Comprehensive Cancer Network (NCCN) and the International Study Group of Pancreatic Surgery (ISGPS) are eligible for inclusion. The study is observational. Quality of life will be assessed in all study participants. The primary outcomes are exploration rates, resection rates and overall survival.
Eligibility criteria
Inclusion Criteria: * Confirmed or suspected invasive pancreatic primary tumor * Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines Exclusion Criteria: * Suspected endocrine tumor * Suspected non-pancreatic periampullary tumor * Distant metastasis * Age \< 18 years * Patient unable to understand verbal or written information interfering with informed consent or treatment * Mental or organic disorder interfering with informed consent or treatments
Study design
Enrollment target: 300 participants
Age groups: adult, older_adult
Timeline
Starts: 2022-04-19
Estimated completion: 2028-05
Last updated: 2022-11-30
Primary outcomes
  • Median Overall Survival (From date of inclusion until the date of death from any cause, assessed up to 72 months)
  • Resection (From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months)
Sponsor
Umeå University · other
With: University Hospital, Linkoeping, Lund University Hospital, Sahlgrenska University Hospital, Karolinska University Hospital, University Hospital, Umeå
Contacts & investigators
ContactOskar Franklin, MD/PhD · contact · oskar.franklin@umu.se · +46730458558
ContactAgneta Karhu · contact · agneta.karhu@umu.se
All locations (1)
Surgical Clinic at Umeå University HospitalRecruiting
Umeå, Sweden
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer · TrialPath